
After the intervention, the proportion of BAPB rose from ~5.9% to ~8.2%, and fecal butyric acid increased from 0.99 mg/g to 1.43 mg/g. One month after stopping BARLEYMAX®, BAPB levels returned close to baseline (≈ 5.4%) and butyric acid dropped to 0.87 mg/g. These results support the view that BARLEYMAX® acts as a prebiotic – stimulating beneficial gut bacteria and boosting production of butyric acid, a short-chain fatty acid linked with gut and immune health.





















